Skip to main content
. Author manuscript; available in PMC: 2021 Jun 1.
Published in final edited form as: Exp Neurol. 2020 Mar 3;328:113272. doi: 10.1016/j.expneurol.2020.113272

Figure 15. CCR5 blockade during HIV+ PBML trafficking at the human in vitro BNB under flow.

Figure 15.

0.1 μg/mL of function neutralizing mouse anti-human CCR5 antibody maximally inhibited a single HIV+ cART-naïve PBML adhesion/ migration at the in vitro basal human BNB, mimicking conditions that may occur during the early stages of HIV infection, using our published leukocyte-BNB dynamic trafficking assay. Numbers are normalized to trafficking measured during basal PBML migration without antagonists or agonists.